Skip to main content
SpringerLink
Log in

Decitabine induces IRF7-mediated immune responses in p53-mutated triple-negative breast cancer: a clinical and translational study

  • Research Article
  • Published:
Frontiers of Medicine Aims and scope Submit manuscript

Abstract

p53 is mutated in half of cancer cases. However, no p53-targeting drugs have been approved. Here, we reposition decitabine for triple-negative breast cancer (TNBC), a subtype with frequent p53 mutations and extremely poor prognosis. In a retrospective study on tissue microarrays with 132 TNBC cases, DNMT1 overexpression was associated with p53 mutations (P = 0.037) and poor overall survival (OS) (P = 0.010). In a prospective DEciTabinE and Carboplatin in TNBC (DETECT) trial (NCT03295552), decitabine with carboplatin produced an objective response rate (ORR) of 42% in 12 patients with stage IV TNBC. Among the 9 trialed patients with available TP53 sequencing results, the 6 patients with p53 mutations had higher ORR (3/6 vs. 0/3) and better OS (16.0 vs. 4.0 months) than the patients with wild-type p53. In a mechanistic study, isogenic TNBC cell lines harboring DETECT-derived p53 mutations exhibited higher DNMT1 expression and decitabine sensitivity than the cell line with wild-type p53. In the DETECT trial, decitabine induced strong immune responses featuring the striking upregulation of the innate immune player IRF7 in the p53-mutated TNBC cell line (upregulation by 16-fold) and the most responsive patient with TNBC. Our integrative studies reveal the potential of repurposing decitabine for the treatment of p53-mutated TNBC and suggest IRF7 as a potential biomarker for decitabine-based treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tannock IF, Hickman JA. Limits to personalized cancer medicine. N Engl J Med 2016; 375(13): 1289–1294

    Article  PubMed  Google Scholar 

  2. Prasad V. Perspective: The precision-oncology illusion. Nature 2016; 537(7619): S63

    Article  PubMed  CAS  Google Scholar 

  3. Joerger AC, Fersht AR. The p53 pathway: origins, inactivation in cancer, and emerging therapeutic approaches. Annu Rev Biochem 2016; 85(1): 375–404

    Article  PubMed  CAS  Google Scholar 

  4. Muller PAJ, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 2014; 25(3): 304–317

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Muller PAJ, Vousden KH. p53 mutations in cancer. Nat Cell Biol 2013; 15(1): 2–8

    Article  PubMed  CAS  Google Scholar 

  6. Sabapathy K, Lane DP. Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others. Nat Rev Clin Oncol 2018; 15(1): 13–30

    Article  PubMed  CAS  Google Scholar 

  7. Loh SN. Arsenic and an old place: rescuing p53 mutants in cancer. Cancer Cell 2021; 39(2): 140–142

    Article  PubMed  CAS  Google Scholar 

  8. Gummlich L. ATO stabilizes structural p53 mutants. Nat Rev Cancer 2021; 21(3): 141

    Article  PubMed  CAS  Google Scholar 

  9. Chen S, Wu JL, Liang Y, Tang YG, Song HX, Wu LL, Xing YF, Yan N, Li YT, Wang ZY, Xiao SJ, Lu X, Chen SJ, Lu M. Arsenic trioxide rescues structural p53 mutations through a cryptic allosteric site. Cancer Cell 2021; 39(2): 225–239.e8

    Article  PubMed  Google Scholar 

  10. Basu A, Bodycombe NE, Cheah JH, Price EV, Liu K, Schaefer GI, Ebright RY, Stewart ML, Ito D, Wang S, Bracha AL, Liefeld T, Wawer M, Gilbert JC, Wilson AJ, Stransky N, Kryukov GV, Dancik V, Barretina J, Garraway LA, Hon CSY, Munoz B, Bittker JA, Stockwell BR, Khabele D, Stern AM, Clemons PA, Shamji AF, Schreiber SL. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell 2013; 154(5): 1151–1161

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Leijen S, van Geel RMJM, Sonke GS, de Jong D, Rosenberg EH, Marchetti S, Pluim D, van Werkhoven E, Rose S, Lee MA, Freshwater T, Beijnen JH, Schellens JHM. Phase II study of WEE1 inhibitor AZD1775 plus carboplatin in patients with TP53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months. J Clin Oncol 2016; 34(36): 4354–4361

    Article  PubMed  CAS  Google Scholar 

  12. Xu L, Gu ZH, Li Y, Zhang JL, Chang CK, Pan CM, Shi JY, Shen Y, Chen B, Wang YY, Jiang L, Lu J, Xu X, Tan JL, Chen Y, Wang SY, Li X, Chen Z, Chen SJ. Genomic landscape of CD34+ hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers. Proc Natl Acad Sci U S A 2014; 111(23): 8589–8594

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Chang C, Zhao Y, Xu F, Li X. A primary study of the gene mutations in predicting treatment response to decitabine in patients with MDS. Blood 2015; 126(23): 1689

    Article  Google Scholar 

  14. Chang CK, Zhao YS, Xu F, Guo J, Zhang Z, He Q, Wu D, Wu LY, Su JY, Song LX, Xiao C, Li X. TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes. Br J Haematol 2017; 176(4): 600–608

    Article  PubMed  CAS  Google Scholar 

  15. Wu J, Li Y, Wu J, Song H, Tang Y, Yan N, Wu L, Zhang S, Chang C, Lu M. Decitabine activates type I interferon signaling to inhibit p53-deficient myeloid malignant cells. Clin Transl Med 2021; 11(11): e593

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Welch JS, Petti AA, Miller CA, Fronick CC, O’Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, Lee YS, Wartman LD, Uy GL, Ghobadi A, Tomasson MH, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Cashen AF, Schroeder MA, Jacoby MA, Heath SE, Luber K, Janke MR, Hantel A, Khan N, Sukhanova MJ, Knoebel RW, Stock W, Graubert TA, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med 2016; 375(21): 2023–2036

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, Lee C, Barrett S, Reade S, Jadayel D, Tang A, Bellenger K, Mackay L, Setanoians A, Schätzlein A, Twelves C, Kaye SB, Brown R. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 2007; 25(29): 4603–4609

    Article  PubMed  CAS  Google Scholar 

  18. Samlowski WE, Leachman SA, Wade M, Cassidy P, Porter-Gill P, Busby L, Wheeler R, Boucher K, Fitzpatrick F, Jones DA, Karpf AR. Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. J Clin Oncol 2005; 23(17): 3897–3905

    Article  PubMed  CAS  Google Scholar 

  19. Fu X, Zhang Y, Wang X, Chen M, Wang Y, Nie J, Meng Y, Han W. Low dose decitabine combined with taxol and platinum chemotherapy to treat refractory/recurrent ovarian cancer: an open-label, single-arm, phase I/II study. Curr Protein Pept Sci 2015; 16(4): 329–336

    Article  PubMed  CAS  Google Scholar 

  20. Matei D, Fang F, Shen C, Schilder J, Arnold A, Zeng Y, Berry WA, Huang T, Nephew KP. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res 2012; 72(9): 2197–2205

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  21. Zhang Y, Mei Q, Liu Y, Li X, Brock MV, Chen M, Dong L, Shi L, Wang Y, Guo M, Nie J, Han W. The safety, efficacy, and treatment outcomes of a combination of low-dose decitabine treatment in patients with recurrent ovarian cancer. Oncoimmunology 2017; 6(9): e1323619

    Article  PubMed  PubMed Central  Google Scholar 

  22. van der Westhuizen A, Knoblauch N, Graves MC, Levy R, Vilain RE, Bowden NA. Pilot early phase II study of decitabine and carboplatin in patients with advanced melanoma. Medicine (Baltimore) 2020; 99(25): e20705

    Article  PubMed  CAS  Google Scholar 

  23. Stathis A, Hotte SJ, Chen EX, Hirte HW, Oza AM, Moretto P, Webster S, Laughlin A, Stayner LA, McGill S, Wang L, Zhang WJ, Espinoza-Delgado I, Holleran JL, Egorin MJ, Siu LL. Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin’s lymphomas. Clin Cancer Res 2011; 17(6): 1582–1590

    Article  PubMed  CAS  Google Scholar 

  24. Leroy B, Anderson M, Soussi T. TP53 mutations in human cancer: database reassessment and prospects for the next decade. Hum Mutat 2014; 35(6): 672–688

    Article  PubMed  CAS  Google Scholar 

  25. Fang F, Balch C, Schilder J, Breen T, Zhang S, Shen C, Li L, Kulesavage C, Snyder AJ, Nephew KP, Matei DE. A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer 2010; 116(17): 4043–4053

    Article  PubMed  CAS  Google Scholar 

  26. Yu J, Qin B, Moyer AM, Nowsheen S, Liu T, Qin S, Zhuang Y, Liu D, Lu SW, Kalari KR, Visscher DW, Copland JA, McLaughlin SA, Moreno-Aspitia A, Northfelt DW, Gray RJ, Lou Z, Suman VJ, Weinshilboum R, Boughey JC, Goetz MP, Wang L. DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 2018; 128(6): 2376–2388

    Article  PubMed  PubMed Central  Google Scholar 

  27. Stathis A, Hotte SJ, Chen EX, Hirte HW, Oza AM, Moretto P, Webster S, Laughlin A, Stayner LA, McGill S, Wang L, Zhang WJ, Espinoza-Delgado I, Holleran JL, Egorin MJ, Siu LL. Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin’s lymphomas. Clin Cancer Res 2011; 17(6): 1582–1590

    Article  PubMed  CAS  Google Scholar 

  28. Patel K, Dickson J, Din S, Macleod K, Jodrell D, Ramsahoye B. Targeting of 5-aza-2′-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme. Nucleic Acids Res 2010; 38(13): 4313–4324

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Creusot F, Acs G, Christman JK. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′-deoxycytidine. J Biol Chem 1982; 257(4): 2041–2048

    Article  PubMed  CAS  Google Scholar 

  30. Stewart DJ, Issa JP, Kurzrock R, Nunez MI, Jelinek J, Hong D, Oki Y, Guo Z, Gupta S, Wistuba II. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res 2009; 15(11): 3881–3888

    Article  PubMed  CAS  Google Scholar 

  31. Yu J, Qin B, Moyer AM, Nowsheen S, Liu T, Qin S, Zhuang Y, Liu D, Lu SW, Kalari KR, Visscher DW, Copland JA, McLaughlin SA, Moreno-Aspitia A, Northfelt DW, Gray RJ, Lou Z, Suman VJ, Weinshilboum R, Boughey JC, Goetz MP, Wang L. DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 2018; 128(6): 2376–2388

    Article  PubMed  PubMed Central  Google Scholar 

  32. Köbel M, Reuss A, du Bois A, Kommoss S, Kommoss F, Gao D, Kalloger SE, Huntsman DG, Gilks CB. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol 2010; 222(2): 191–198

    Article  PubMed  Google Scholar 

  33. Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J, Boyd N, Pike J, Anglesio M, Kwon JS, Karnezis AN, Huntsman DG, Gilks CB, McAlpine JN. Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer 2017; 123(5): 802–813

    Article  PubMed  CAS  Google Scholar 

  34. Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, Yang W, Senz J, Boyd N, Karnezis AN, Huntsman DG, Gilks CB, McAlpine JN. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer 2015; 113(2): 299–310

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  35. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490(7418): 61–70

    Article  Google Scholar 

  36. Pereira B, Chin SF, Rueda OM, Vollan HKM, Provenzano E, Bardwell HA, Pugh M, Jones L, Russell R, Sammut SJ, Tsui DWY, Liu B, Dawson SJ, Abraham J, Northen H, Peden JF, Mukherjee A, Turashvili G, Green AR, McKinney S, Oloumi A, Shah S, Rosenfeld N, Murphy L, Bentley DR, Ellis IO, Purushotham A, Pinder SE, Børresen-Dale AL, Earl HM, Pharoah PD, Ross MT, Aparicio S, Caldas C. Erratum: The somatic mutation profiles of 2433 breast cancers refine their genomic and transcriptomic landscapes. Nat Commun 2016; 7(1): 11908

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  37. Maisano R, Zavettieri M, Azzarello D, Raffaele M, Maisano M, Bottari M, Nardi M. Carboplatin and gemcitabine combination in metastatic triple-negative anthracycline- and taxane-pretreated breast cancer patients: a phase II study. J Chemother 2011; 23(1): 40–43

    Article  PubMed  CAS  Google Scholar 

  38. Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder SE, Bliss JM. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med 2018; 24(5): 628–637

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  39. O’Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M, Robert N, Hellerstedt B, Saleh M, Richards P, Specht JM, Yardley DA, Carlson RW, Finn RS, Charpentier E, Garcia-Ribas I, Winer EP. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol 2014; 32(34): 3840–3847

    Article  PubMed  Google Scholar 

  40. Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman AR, Borger DR, Finkelstein DM, Garber JE, Ryan PD, Winer EP, Goss PE, Ellisen LW. TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol 2015; 33(17): 1902–1909

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  41. Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 2012; 30(21): 2615–2623

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  42. Wu J, Song H, Wang Z, Lu M. Three optimized assays for the evaluation of compounds that can rescue p53 mutants. STAR Protoc 2021; 2(3): 100688

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Christman JK. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002; 21(35): 5483–5495

    Article  PubMed  CAS  Google Scholar 

  44. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 2008; 123(1): 8–13

    Article  PubMed  CAS  Google Scholar 

  45. Brady CA, Jiang D, Mello SS, Johnson TM, Jarvis LA, Kozak MM, Kenzelmann Broz D, Basak S, Park EJ, McLaughlin ME, Karnezis AN, Attardi LD. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 2011; 145(4): 571–583

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  46. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2010; 2(1): a001008

    Article  PubMed  PubMed Central  Google Scholar 

  47. Bhattacharya S, Dunn P, Thomas CG, Smith B, Schaefer H, Chen J, Hu Z, Zalocusky KA, Shankar RD, Shen-Orr SS, Thomson E, Wiser J, Butte AJ. ImmPort, toward repurposing of open access immunological assay data for translational and clinical research. Sci Data 2018; 5(1): 180015

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  48. Colina R, Costa-Mattioli M, Dowling RJ, Jaramillo M, Tai LH, Breitbach CJ, Martineau Y, Larsson O, Rong L, Svitkin YV, Makrigiannis AP, Bell JC, Sonenberg N. Translational control of the innate immune response through IRF-7. Nature 2008; 452(7185): 323–328

    Article  PubMed  CAS  Google Scholar 

  49. Sgarbanti M, Marsili G, Remoli AL, Orsatti R, Battistini A. IRF-7: new role in the regulation of genes involved in adaptive immunity. Ann N Y Acad Sci 2007; 1095(1): 325–333

    Article  PubMed  CAS  Google Scholar 

  50. Lu R, Au WC, Yeow WS, Hageman N, Pitha PM. Regulation of the promoter activity of interferon regulatory factor-7 gene. Activation by interferon snd silencing by hypermethylation. J Biol Chem 2000; 275(41): 31805–31812

    PubMed  CAS  Google Scholar 

  51. Yu J, Zhang HY, Ma ZZ, Lu W, Wang YF, Zhu JD. Methylation profiling of twenty four genes and the concordant methylation behaviours of nineteen genes that may contribute to hepatocellular carcinogenesis. Cell Res 2003; 13(5): 319–333

    Article  PubMed  CAS  Google Scholar 

  52. Li Q, Tang L, Roberts PC, Kraniak JM, Fridman AL, Kulaeva OI, Tehrani OS, Tainsky MA. Interferon regulatory factors IRF5 and IRF7 inhibit growth and induce senescence in immortal Li-Fraumeni fibroblasts. Mol Cancer Res 2008; 6(5): 770–784

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We sincerely appreciate all of the participants of the DETECT trial for their coordination and devotion. We also would like to thank all the specialist nurses and secretaries for their diligent work in database maintenance and follow-up update.

These studies were supported by the National Natural Science Foundation of China (No. 82130075 to Min Lu, No. 82073292 to Min Lu, No. 81772797 to Xiaosong Chen, No. 82072937 to Xiaosong Chen, No. 82072897 to Kunwei Shen, No. 82002773 to Zheng Wang, No. 81900157 to Ying Liang), SJTU Trans-med Awards Research (to Min Lu), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine (No. 828318 to Min Lu and No. 20172007 to Xiaosong Chen), Shanghai Excellent Youth Academic Leader (No. 20XD1422700 to Min Lu), Program of Shanghai Science and Technology Committee (No. 21S11900100 to Min Lu), Dawn Program of Shanghai Education Commission (No. 21SG18 to Min Lu), Samuel Waxman Cancer Research Foundation (to Min Lu), and Foundation of National Facility for Translational Medicine (Shanghai) (No. NRCTM(SH)-2021-08).

Author information

Author notes

  1. Contributed equally to this work.

Authors and Affiliations

  1. Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China

    Haoyu Wang, Zheng Wang, Qing Qu, Jiahui Huang, Kunwei Shen & Xiaosong Chen

  2. Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine (Shanghai), Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China

    Zhengyuan Wang, Yuntong Li, Ni Yan, Lili Wu, Ying Liang, Jiale Wu, Huaxin Song & Min Lu

  3. Department of Hematology, Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China

    Xiaoyang Li

  4. Department of Hematology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, 200025, China

    Chunkang Chang

Authors
  1. Haoyu Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhengyuan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zheng Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaoyang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuntong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ni Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lili Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ying Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jiale Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Huaxin Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Qing Qu
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Jiahui Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Chunkang Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Kunwei Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Xiaosong Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Min Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Kunwei Shen, Xiaosong Chen or Min Lu.

Ethics declarations

Conflicts of interest Haoyu Wang, Zhengyuan Wang, Zheng Wang, Xiaoyang Li, Yuntong Li, Ni Yan, Lili Wu, Ying Liang, Jiale Wu, Huaxin Song, Qing Qu, Jiahui Huang, Chunkang Chang, Kunwei Shen, Xiaosong Chen, and Min Lu have declared that they have no conflict of interest.

The study was approved by the Ruijin Hospital Ethics Committee and the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Informed consent was obtained from all patients for being included in the study.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, H., Wang, Z., Wang, Z. et al. Decitabine induces IRF7-mediated immune responses in p53-mutated triple-negative breast cancer: a clinical and translational study. Front. Med. (2023). https://doi.org/10.1007/s11684-023-1016-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11684-023-1016-8

Keywords

Search

Navigation